此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kg

2026年11月14日 更新者:Merck Sharp & Dohme LLC

A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Oral Doravirine/Islatravir (100 mg/0.25 mg) in Pediatric Participants With HIV-1 Infection Who Are Virologically Suppressed or Treatment-Naïve, Are Less Than 18 Years of Age, and Weigh Greater Than or Equal to 35 kg

This is a phase 2 study of the pharmacokinetics, safety, and efficacy of oral doravirine/islatravir (100 mg/0.25 mg) [MK-8591A] in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection who are virologically suppressed or treatment-naive.

The Base Study will last from Day 1 to Week 96. At Week 96, participants will be given the option to participate in an optional Study Extension and receive DOR/ISL until Week 240 or until it becomes commercially accessible, whichever is first.

研究概览

地位

尚未招聘

干预/治疗

研究类型

介入性

注册 (估计的)

45

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Florida
      • Tampa、Florida、美国、33612
        • University of South Florida ( Site 1505)
        • 接触:
          • Study Coordinator
          • 电话号码:813-821-8039
    • New York
      • The Bronx、New York、美国、10467
        • The Children's Hospital at Montefiore ( Site 1507)
        • 接触:
          • Study Coordinator
          • 电话号码:718-741-2497

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

不超过 18年 (孩子、成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Pediatric participant with HIV-1 <18 years of age
  • Body weight ≥35 kg
  • Is TN (HIV-1 positive with plasma HIV-1 RNA ≥500 copies/mL) or VS (HIV-1 positive at screening with plasma HIV-1 RNA <50 copies/mL AND has received stable, continuous 2- or 3-drug antiretroviral therapy (ART) for ≥3 months prior to providing informed consent)

Exclusion Criteria:

  • HIV-2 infection
  • Hypsensitivity/contraindication to any components of study medication or as determined by the investigator
  • Has an active diagnosis of hepatitis due to any cause
  • history of malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or cutaneous Kaposi's sarcoma
  • Has a history or current evidence of any condition (including active tuberculosis infection, COVID-19, or other infections), therapy, laboratory abnormality, or other circumstance (including drug or alcohol use or dependence) that might, in the opinion of the investigator, confound the results of the study
  • Is taking or is anticipated to require systemic immunosuppressive therapy, immune modulators, or any prohibited therapies

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:DOR/ISL

Participants receive DOR/ISL 100 mg/0.25 mg once daily (qd) for 96 weeks. Participants will have the option to participate in the Study Extension and receive DOR/ISL until Week 240 or it becomes commercially available, whichever is first.

DOR/ISL 100 mg/0.25 mg tablet taken by mouth qd

其他名称:
  • MK-8591A

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Area under the plasma conentration-time curve from dosing to 24 hours postdose (AUC0-24) of ISL
大体时间:At designated timepoints on Day 28

The plasma AUC0-24 will be assessed.

At designated timepoints on Day 28
Maximum plasma concentration (Cmax) of ISL
大体时间:At designated timepoints on Day 28

The plasma Cmax will be assessed.

At designated timepoints on Day 28
Time to maximum plasma concentration (Tmax) of ISL
大体时间:At designated timepoints on Day 28

The plasma Tmax will be assessed.

At designated timepoints on Day 28
Apparent plasma terminal half-life (t½) of ISL
大体时间:At designated timepoints on Day 28

The plasma t½ will be assessed.

At designated timepoints on Day 28
Apparent clearance (CL/F) of ISL
大体时间:At designated timepoints on Day 28

The CL/F will be assessed.

At designated timepoints on Day 28
Volume of distribution (Vz/F) of ISL
大体时间:At designated timepoints on Day 28

The Vz/F will be assessed.

At designated timepoints on Day 28
Percentage of participants with ≥1 adverse event (AE) through Week 24
大体时间:Up to ~24 weeks

The percentage of participants with AE(s) will be assessed.

Up to ~24 weeks
Percentage of participants discontinuing from study therapy due to AE(s) through Week 24
大体时间:Up to ~24 weeks

The percentage of participants discontinuing from therapy due to AE(s) will be assessed.

Up to ~24 weeks

次要结果测量

结果测量
措施说明
大体时间
Percentage of participants with ≥1 AE through Week 96
大体时间:Up to 96 weeks

The percentage of participants with AE(s) will be assessed.

Up to 96 weeks
Percentage of participants discontinuing from study therapy due to AE(s) through Week 96
大体时间:Up to 96 weeks

The percentage of participants with AE(s) will be assessed.

Up to 96 weeks
Percentage of virologically-suppressed (VS) participants with Human Immunodeficiency Virus Type 1 (HIV-1) ribonucleic acid (RNA) ≥50 copies/mL
大体时间:Weeks 24, 48, and 96

The percentage of VS participants with HIV-1 RNA ≥50 copies/mL will be assessed.

Weeks 24, 48, and 96
Percentage of VS participants with HIV-1 RNA <50 copies/mL
大体时间:Weeks 24, 48, and 96

The percentage of VS participants with HIV-1 RNA <50 copies/mL will be assessed.

Weeks 24, 48, and 96
Percentage of VS participants with HIV-1 RNA <200 copies/mL
大体时间:Weeks 24, 48, and 96

The percentage of VS participants with HIV-1 RNA <200 copies/mL will be assessed.

Weeks 24, 48, and 96
Percentage of treatment-naive (TN) participants with HIV-1 RNA <50 copies/mL
大体时间:Weeks 24, 48, and 96

The percentage of TN participants with HIV-1 RNA <50 copies/mL will be assessed.

Weeks 24, 48, and 96
Percentage of TN participants with HIV-1 RNA <200 copies/mL
大体时间:Weeks 24, 48, and 96

The percentage of TN participants with HIV-1 RNA <200 copies/mL will be assessed.

Weeks 24, 48, and 96
Change from baseline in CD4+ T-cell counts in VS and TN participants
大体时间:Weeks 24, 48, and 96

The change from baseline in CD4+ T-cell counts will be assessed in VS and TN participants.

Weeks 24, 48, and 96
Percentage of participants with viral drug resistance to DOR or ISL
大体时间:Weeks 24, 48, 96, and 144

The percentage of participants with viral resistance-associated substitutions will be assessed during Weeks 24, 48, 96, and 144.

Weeks 24, 48, 96, and 144

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月23日

初级完成 (估计的)

2029年9月24日

研究完成 (估计的)

2033年12月23日

研究注册日期

首次提交

2026年10月2日

首先提交符合 QC 标准的

2026年10月2日

首次发布 (实际的)

2026年10月7日

研究记录更新

最后更新发布 (实际的)

2026年11月17日

上次提交的符合 QC 标准的更新

2026年11月14日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅